| Product | Indication | Drug discovery | Lead optimization | Non-clinical study | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ |
|---|---|---|---|---|---|---|---|
| SC-01 | Breast cancer | ||||||
| SC-02 | NSCLC Glioma |
||||||
| SC-04 | Neurodegenerative disorders | ||||||
| SC-05 | Ovarian cancer Endometriosis |
||||||
| SC-06 | Hematological neoplasms |
SC-01
Indication：Breast cancer
| Drug discovery | Lead optimization | Non-clinical study | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ |
|---|---|---|---|---|---|
SC-02
Indication：NSCLC、Glioma
| Drug discovery | Lead optimization | Non-clinical study | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ |
|---|---|---|---|---|---|
SC-04
Indication：Neurodegenerative disorders
| Drug discovery | Lead optimization | Non-clinical study | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ |
|---|---|---|---|---|---|
SC-05
Indication：Ovarian cancer、Endometriosis
| Drug discovery | Lead optimization | Non-clinical study | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ |
|---|---|---|---|---|---|
SC-06
Indication：Hematological neoplasms
| Drug discovery | Lead optimization | Non-clinical study | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ |
|---|---|---|---|---|---|